MONOCYTE CHEMOTACTIC PROTEIN AND RESPONSE TO PEGYLATED INTERFERON-ALPHA-2A TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 4 | ||
| Journal of the Egyptian Society of Parasitology | ||
| Article 13, Volume 46, Issue 1, April 2016, Pages 117-124 PDF (3.16 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/jesp.2016.88959 | ||
| Authors | ||
| AMAL A. MOHAMED1; OLA SAYED2; OMNIA E. ALI3; GHADIR A. SAYED3; ZAINAB MOUSTFA4; WALEED AHMED ELAGAWY5 | ||
| 1Departments of Biochemistry, National Hepatology and Tropical Medicine Institute, Faculty of Pharmacy, Al-Azhar University, Egypt. | ||
| 2Department of Biochemistry, Faculty of Pharmacy, Al-Azhar University, Egypt. | ||
| 3Department of Biochemistry, Faculty of Pharmacy Egyptian Russian University, Helwan, Egypt. | ||
| 4Department of Radiology, National Hepatology and Tropical Medicine Institute, Cairo, Egypt. | ||
| 5Department of Tropical Medicine, National Hepatology and Tropical Medicine Institute, Cairo, Egypt. | ||
| Abstract | ||
| The prevalence of hepatitis C virus (HCV) infection varies across the world, with the highest number of infections reported in Egypt. Monocyte chemotactic protein-1 (MCP-1) is a potent chemokine, and its hepatic expression is up-regulated during chronic HCV infection. Fifty naive patients with chronic hepatitis C in National Hepatology & Tropical Medicine Research Institute and 20 healthy volunteers as controls were enrolled in a prospective study designed with strict inclusion criteria to nullify the effect of confounding variables and further minimize selection bias. Fifty naïve patients were treated with PEG-IFN-a2b, at a dose of 180lg/kg subcutaneously every week plus ribavirin at a dose of 1000–1200 mg/day, according to the patient's body weight, for 48 weeks. Quantification of HCV-RNA by real-time PCR and MCP-1 by ELISA were performed for every patient and controls. There was a statistically significant difference between patients and control group as regards the quantity of MCP-1 (P <0.05) (Mann–Whitney test) (P =0.004). There was a significant difference between responders and nonresponses regarding MCP-1 (P < 0.05), responders showed a higher percentage of cases with initial MCP-1< 306 (P < 0.05). We conclude the importance of the detection of MCP-1 expression at the start of therapy as a factor for assessing the likelihood of HCV genotype 4 patients to achieving a sustained virological response to treatment with IFN-a2 in combination with ribavirin. | ||
| Keywords | ||
| Egypt; Genotype 4; Hepatitis C virus; Interferon; MCP-1 | ||
|
Statistics Article View: 115 PDF Download: 187 |
||
